CCL

Összesen 9 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM099048
Első szerző:Dzsudzsák Erika
Cím:Profiling of lactate dehydrogenase isoenzymes in COVID-19 disease / Erika Dzsudzsák, Renáta Sütő, Marianna Pócsi, Miklós Fagyas, Zoltán Szentkereszty, Béla Nagy Jr.
Dátum:2021
Megjegyzések:Introduction Serum total lactate dehydrogenase (LDH) activity was elevated and showed a positive correlation with disease severity and outcome in severe COVID-19 disease. However, it is still unknown whether the relative abundance or calculated activity of any LDH isoenzyme is predominately increased in COVID-19 subjects. Methods Twenty-two consecutive patients suffered from moderate or severe COVID-19 pneumonia were recruited into this study who showed enhanced total LDH activity. The ratio of LDH isoenzyme activities was further investigated using gel electrophoresis (Hydragel, Sebia) with densitometric evaluation. Calculated act ivity values of these isoenzymes were correlated with routine laboratory parameters, the degree of lungparenchymal affection based on chest CT and clinical outcome. Results Total LDH activity was raised in the range of 272-2141 U/L and significantly correlated with calculated LDH-3 and LDH-4 activities (r=0.765, P=0.0001; and r=0.783, P=0.0001, respectively). In contrast, the relative abundance of neither LDH isoenzyme was exclusively abnormal in COVID-19 patients. Calculated activity of LDH-3 and LDH-4 demonstrated a modest but statistically significant association with serum ferritin (r=0.437, P=0.042; r=0.505, P=0.016, respectively). When the relationship between the severity of pulmonary affection by SARS-CoV-2 infection and relative abundance of LDH isoenzymes was studied, a larger ratio of mid-zone fractions was observed in the presence of ? 50% lung parenchymal involvement. Finally, regardless of LDH isoenzyme pattern, abnormal relat ive ratio of LDH-4 and higher calculated LDH-3 and LDH-4 activity values were detected in subjects with unfavorable outcome. Conclusion No characteristic profile of LDH isoenzymes can be detected in COVID-19 pneumonia, however, elevated activities of LDH-3 and LDH-4 are associated with worse clinical outcomes.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
SARS-Cov-2
COVID-19
inflammation
LDH
electrophoresis
clinical outcome
Megjelenés:The Journal of the International Federation of Clinical Chemistry and Laboratory Medicine. - 32 : 4 (2021), p. 432-441. -
További szerzők:Sütő Renáta (1986-) (aneszteziológus) Pócsi Marianna (1989-) (klinikai laboratóriumi kutató) Fagyas Miklós (1984-) (orvos) Szentkereszty Zoltán Nagy Béla Jr. (1980-) (labordiagnosztikai szakorvos)
Pályázati támogatás:FK 135327
OTKA
FK 128809
OTKA
ÚNKP21-3-I-DE-255
Egyéb
ÚNKP-21-5-DE-458
Egyéb
BO/00069/21/5
MTA
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM103836
035-os BibID:(wos)000854410800001 (Scopus)85138156081
Első szerző:Fagyas Miklós (orvos)
Cím:The majority of severe COVID-19 patients develop anti-cardiac autoantibodies / Fagyas Miklós, Nagy Béla, Ráduly Arnold Péter, Mányiné Siket Ivetta, Mártha Lilla, Erdősi Gábor, Sipka Sándor, Enyedi Enikő, Szabó Attila Ádám, Pólik Zsófia, Kappelmayer János, Papp Zoltán, Borbély Attila, Szabó Tamás, Balla József, Balla György, Bai Péter, Bácsi Attila, Tóth Attila
Dátum:2022
ISSN:2509-2715 2509-2723
Megjegyzések:Severe cases of COVID-19 are characterized by an inflammatory burst, which is accompanied by multiorgan failure. The elderly population has higher risk for severe or fatal outcome for COVID-19. Inflammatory mediators facilitate the immune system to combat viral infection by producing antibodies against viral antigens. Several studies reported that the pro-inflammatory state and tissue damage in COVID-19 also promotes autoimmunity by autoantibody generation. We hypothesized that a subset of these autoantibodies targets cardiac antigens. Here we aimed to detect anti-cardiac autoantibodies in severe COVID-19 patients during hospitalization. For this purpose, 104 COVID-19 patients were recruited, while 40 heart failure patients with dilated cardiomyopathy and 20 patients with severe aortic stenosis served as controls. Patients were tested for anti-cardiac autoantibodies, using human heart homogenate as a bait. Follow-up samples were available in 29 COVID-19 patients. Anti-cardiac autoantibodies were detected in 68% (71 out of 104) of severe COVID-19 patients. Overall, 39% of COVID-19 patients had anti-cardiac IgG autoantibodies, while 51% had anti-cardiac autoantibodies of IgM isotype. Both IgG and IgM anti-cardiac autoantibodies were observed in 22% of cases, and multiple cardiac antigens were targeted in 38% of COVID-19 patients. These anti-cardiac autoantibodies targeted a diverse set of myocardial proteins, without apparent selectivity. As controls, heart failure patients (with dilated cardiomyopathy) had similar occurrence of IgG (45%, p = 0.57) autoantibodies, while significantly lower occurrence of IgM autoantibodies (30%, p = 0.03). Patients with advanced aortic stenosis had significantly lower number of both IgG (11%, p = 0.03) and IgM (10%, p < 0.01) type anti-cardiac autoantibodies than that in COVID-19 patients. Furthermore, we detected changes in the anti-cardiac autoantibody profile in 7 COVID-19 patients during hospital treatment. Surprisingly, the presence of these anti-cardiac autoantibodies did not affect the clinical outcome and the prevalence of the autoantibodies did not differ between the elderly (over 65 years) and the patients younger than 65 years of age. Our results demonstrate that the majority of hospitalized COVID-19 patients produce novel anti-cardiac IgM autoantibodies. COVID-19 also reactivates resident IgG autoantibodies. These autoantibodies may promote autoimmune reactions, which can complicate post-COVID recuperation, contributing to post-acute sequelae of COVID-19 (long COVID).
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
COVID-19
Anti-cardiac autoantibodies
SARS-CoV-2
Megjelenés:GeroScience. - 44 (2022), p. 2347-2360. -
További szerzők:Nagy Béla Jr. (1980-) (labordiagnosztikai szakorvos) Ráduly Arnold Péter (1993-) Mányiné Siket Ivetta (1962-) (laborasszisztens) Mártha Lilla Erdősi Gábor Sipka Sándor ifj. (1980-) (orvos) Enyedi Enikő Edit (1995-) (orvosi laboratóriumi analitikus) Szabó Attila Ádám (1996-) (orvos) Pólik Zsófia Kappelmayer János (1960-) (laboratóriumi szakorvos) Papp Zoltán (1965-) (kardiológus, élettanász) Borbély Attila (1978-) (kardiológus) Szabó Tamás (1968-) (gyermekgyógyász) Balla József (1959-) (belgyógyász, nephrológus) Balla György (1953-) (csecsemő és gyermekgyógyász, neonatológus) Bai Péter (1976-) (biokémikus) Bácsi Attila (1967-) (immunológus) Tóth Attila (1971-) (biológus)
Pályázati támogatás:GINOP-2.3.2-15-2016-00050
GINOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM099912
035-os BibID:(WoS)000787774100002 (Scopus)85121006331
Első szerző:Fagyas Miklós (orvos)
Cím:Circulating ACE2 activity predicts mortality and disease severity in hospitalized COVID-19 patients / Fagyas Miklós, Fejes Zsolt, Sütő Renáta, Nagy Zsuzsanna, Székely Borbála, Pócsi Marianna, Ivády Gergely, Bíró Edina, Bekő Gabriella, Nagy Attila, Kerekes György, Szentkereszty Zoltán, Papp Zoltán, Tóth Attila, Kappelmayer János, Nagy Béla
Dátum:2022
ISSN:1201-9712
Megjegyzések:Objectives Angiotensin-converting enzyme 2 (ACE2) represents the primary receptor for SARS-CoV-2 to enter endothelial cells. Here we investigated circulating ACE2 activity to predict the severity and mortality of COVID-19. Methods Serum ACE2 activity was measured in COVID-19 (110 critically ill and 66 severely ill subjects at hospital admission and 106 follow-up samples) and in 32 non-COVID-19 severe sepsis patients. Associations between ACE2, inflammation-dependent biomarkers, pre-existing comorbidities, and clinical outcomes were studied. Results Initial ACE2 activity was significantly higher in critically ill COVID-19 patients (54.4 [36.7-90.8] mU/L) than in severe COVID-19 (34.5 [25.2-48.7] mU/L; P<0.0001) and non-COVID-19 sepsis patients (40.9 [21.4-65.7] mU/L; P=0.0260) regardless of comorbidities. Circulating ACE2 activity correlated with inflammatory biomarkers and was further elevated during the hospital stay in critically ill patients. Based on ROC-curve analysis and logistic regression test, baseline ACE2 independently indicated the severity of COVID-19 with an AUC value of 0.701 (95% CI [0.621-0.781], P<0.0001). Furthermore, non-survivors showed higher serum ACE2 activity vs. survivors at hospital admission (P<0.0001). Finally, high ACE2 activity (?45.4 mU/L) predicted a higher risk (65 vs. 37%) for 30-day mortality (Log-Rank P<0.0001). Conclusions Serum ACE2 activity correlates with COVID-19 severity and predicts mortality.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
SARS-CoV-2
ACE2
inflammation
COVID-19 disease
biomarker
outcome
sepsis
Megjelenés:International Journal Of Infectious Diseases. - 115 (2022), p. 8-16. -
További szerzők:Fejes Zsolt (1988-) (molekuláris biológus) Sütő Renáta (1986-) (aneszteziológus) Nagy Zsuzsanna (1986-) (élettanász) Székely Borbála Pócsi Marianna (1989-) (klinikai laboratóriumi kutató) Ivády Gergely (1979-) (laboratóriumi szakorvos) Bíró Edina Bekő Gabriella Nagy Attila Csaba (1981-) (megelőző orvostan és népegészségtan szakorvos, epidemiológus) Kerekes György (1973-) (belgyógyász, kardiológus, angiológus) Szentkereszty Zoltán Papp Zoltán (1965-) (kardiológus, élettanász) Tóth Attila (1971-) (biológus) Kappelmayer János (1960-) (laboratóriumi szakorvos) Nagy Béla Jr. (1980-) (labordiagnosztikai szakorvos)
Pályázati támogatás:GINOP-2.3.2-15-2016-00043
GINOP
GINOP-2.3.2-15-2016-00050
GINOP
EFOP-3.6.2-16-2017-00006
EFOP
TKP2020-IKA-04
Egyéb
TKP2020-NKA-04
Egyéb
ÚNKP-21-3-I-DE-255
Egyéb
ÚNKP-21-5-DE-458
Egyéb
BO/00069/21/5
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM090202
035-os BibID:(WoS)000616697100011 (Scopus)85098777092
Első szerző:Nagy Béla Jr. (labordiagnosztikai szakorvos)
Cím:A dramatic rise in serum ACE2 activity in a critically ill COVID-19 patient / Nagy Béla, Fejes Zsolt, Szentkereszty Zoltán, Sütő Renáta, Várkonyi István, Ajzner Éva, Kappelmayer János, Papp Zoltán, Tóth Attila, Fagyas Miklós
Dátum:2021
ISSN:1201-9712
Megjegyzések:Endothelial cells express surface angiotensin-converting enzyme 2 (ACE2), the main receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that promotes the infection of endothelial cells showing activation and damage. Bronchoalveolar lavage fluid from coronavirus disease-2019 (COVID-19) subjects showed a critical imbalance in the renin-angiotensin-aldosterone system with the upregulated expression of ACE2. Recently, intravenous recombinant ACE2 was reported as an effective therapy in severe COVID-19 by blocking the viral entry to target cells. Here, we present a case of a critically ill COVID-19 patient with acute respiratory distress syndrome where circulating ACE2 was first measured to monitor disease prognosis. ACE2 activity increased about 40-fold over the normal range and showed a distinct time course as compared to 2-3-fold higher levels of endothelium biomarkers. Although the level of soluble E-selectin followed the clinical status of our patient similar to ferritin and IL-6 levels, the dramatic rise in serum ACE2 activity may act as an endogenous nonspecific protective mechanism against SARS-CoV-2 infection that preceded the recovery of our patient.
Tárgyszavak:Orvostudományok Klinikai orvostudományok esettanulmány
folyóiratcikk
COVID-19
ACE2
Endothelial cell
Inflammation
Biomarker
Megjelenés:International Journal Of Infectious Diseases. - 103 (2021), p. 412-414. -
További szerzők:Fejes Zsolt (1988-) (molekuláris biológus) Szentkereszty Zoltán Sütő Renáta (1986-) (aneszteziológus) Várkonyi István (1973-) (orvos) Ajzner Éva (1968-) (laboratóriumi szakorvos) Kappelmayer János (1960-) (laboratóriumi szakorvos) Papp Zoltán (1965-) (kardiológus, élettanász) Tóth Attila (1971-) (biológus) Fagyas Miklós (1984-) (orvos)
Pályázati támogatás:EFOP-3.6.2-16-2017-00006
EFOP
GINOP-2.3.2-15-2016-00043
GINOP
FK128809
Egyéb
K132623
Egyéb
ED_18-1-2019-0028
Egyéb
ÚNKP-20-4-II-DE-197
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM116355
035-os BibID:(cikkazonosító)1257072 (WoS)001100984900001 (Scopus)85176425171
Első szerző:Stercel Vivien
Cím:Effect of anti-SARS-CoV-2 BNT162b2 mRNA vaccination on thrombin generation in children with inflammatory bowel disease / Stercel Vivien, Lóczi Linda, Kadenczki Orsolya, Nemes Éva, Nagy Béla, Hodossy-Takács Rebeka, Szabó Attila Ádám, Fagyas Miklós, Kappelmayer János, Szabó Tamás, Bagoly Zsuzsa
Dátum:2023
ISSN:1664-3224
Megjegyzések:Background: Inflammatory bowel disease (IBD) including Crohn's disease (CD) and ulcerative colitis (UC), are associated with higher thrombotic risk and enhanced thrombin generation (TG) in adults. Despite encouraging data reporting vaccine safety and low IBD flare rates in adults with IBD, vaccine hesitancy was demonstrated to be high in families of children with IBD. We aimed to find out whether TG is increased in children with IBD as compared to healthy controls and whether TG parameters show significant changes following SARS-CoV-2 mRNA vaccination.Patients and methodsIn this observational case-control study, 38 children with IBD (CD:18, UC: 20) aged 12-18 years and 62 healthy age-and sex-matched children were enrolled. Blood was collected before the first dose and 2-6 weeks after the second dose of BNT162b2 (Pfizer-BioNTech) mRNA vaccine dose. Blood cell counts, fibrinogen, inflammatory markers (hsCRP, ferritin), anti-SARS-CoV-2 antibody levels were investigated, TG assay was carried-out using platelet-poor plasma. Detailed clinical parameters including disease activity scores (PUCAI, PCDAI) were registered pre-and post- vaccination. A guided questionnaire was used to collect data on adverse reactions (AEs) post- vaccination. Results: Baseline TG parameters did not differ between patients and controls. Endogenous thrombin potential showed a significant positive correlation with markers of inflammation and with PCDAI. Inflammatory parameters and TG did not increase in patients and controls post-vaccination. Vaccination significantly increased antibody levels in all three investigated groups, but post-vaccination anti-SARS-CoV-2 S IgG/IgM levels were below the 5th percentile value of healthy children in more than one third of patients. Those receiving TNF alpha inhibitor therapy presented significantly lower SARS-CoV-2 S IgG/IgM levels as compared to patients on other immunosuppressive regimens. Systemic AEs did not differ between patients and controls while lower rate of local symptoms was found post-vaccination in children with IBD. Only 2 IBD flares were detected 2-6 weeks after the second dose of vaccination. Conclusion: Our study is the first to support the safety and efficacy of anti-SARS-CoV-2 BNT162b2 vaccination in children with IBD with detailed pre-and post-vaccination laboratory data including TG. Results of this study may further increase confidence and reduce vaccine hesitancy in caretakers of pediatric IBD patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
COVID-19
Crohn's disease
inflammatory bowel disease
severe acute respiratory syndrome coronavirus-2
thrombin generation
ulcerative colitis
Megjelenés:Frontiers in Immunology. - 14 (2023), p. 1-12. -
További szerzők:Lóczi Linda Kadenczki Orsolya (1974-) (csecsemő- és gyermekgyógyász) Nemes Éva (1957-) (csecsemő- és gyermekgyógyász, gasztroenterológus) Nagy Béla Jr. (1980-) (labordiagnosztikai szakorvos) Hodossy-Takács Rebeka (1997-) (orvos) Szabó Attila Ádám (1996-) (orvos) Fagyas Miklós (1984-) (orvos) Kappelmayer János (1960-) (laboratóriumi szakorvos) Szabó Tamás (1968-) (gyermekgyógyász) Bagoly Zsuzsa (1978-) (orvos)
Pályázati támogatás:FK128582
NKFIH
K147243
NKFIH
K129287
NKFIH
TKP 2021 EGA-19
Egyéb
UNKP 22-3-II-DE-167
Egyéb
UNKP 23-5-DE-482
Egyéb
POST-COVID2021-33
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM118892
035-os BibID:(Scopus)85183145005 (WoS)001151087100001
Első szerző:Sütő Renáta (aneszteziológus)
Cím:Comparison of Different Vascular Biomarkers for Predicting In-Hospital Mortality in Severe SARS-CoV-2 Infection / Renáta Sütő, Marianna Pócsi, Miklós Fagyas, Edit Kalina, Zsolt Fejes, Zoltán Szentkereszty, János Kappelmayer, Béla Nagy Jr.
Dátum:2024
ISSN:2076-2607
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Microorganisms. - 12 : 1 (2024), p. 1-15. -
További szerzők:Pócsi Marianna (1989-) (klinikai laboratóriumi kutató) Fagyas Miklós (1984-) (orvos) Kalina Edit Fejes Zsolt (1988-) (molekuláris biológus) Szentkereszty Zoltán Kappelmayer János (1960-) (laboratóriumi szakorvos) Nagy Béla Jr. (1980-) (labordiagnosztikai szakorvos)
Pályázati támogatás:POST-COVID2021-33
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM118890
035-os BibID:(Scopus)85179926890 (WoS)001125631500001
Első szerző:Sütő Renáta (aneszteziológus)
Cím:Elevated level of serum human epididymis protein 4 (HE4) predicts disease severity and mortality in COVID-19 pneumonia / Renáta Sütő, Marianna Pócsi, Zsolt Szabó, Zsolt Fejes, Gergely Ivády, György Kerekes, Miklós Fagyas, Attila Nagy, Zoltán Szentkereszty, János Kappelmayer, Béla Nagy Jr.
Dátum:2023
ISSN:1471-2466
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:BMC Pulmonary Medicine. - 23 : 1 (2023), p. 1-11. -
További szerzők:Pócsi Marianna (1989-) (klinikai laboratóriumi kutató) Szabo Zsolt Fejes Zsolt (1988-) (molekuláris biológus) Ivády Gergely (1979-) (laboratóriumi szakorvos) Kerekes György (1973-) (belgyógyász, kardiológus, angiológus) Fagyas Miklós (1984-) (orvos) Nagy Attila Csaba (1981-) (megelőző orvostan és népegészségtan szakorvos, epidemiológus) Szentkereszty Zoltán Kappelmayer János (1960-) (laboratóriumi szakorvos) Nagy Béla Jr. (1980-) (labordiagnosztikai szakorvos)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM112604
035-os BibID:(cikkazonosító)171 (WoS)001025509200007 (Scopus)85164313047
Első szerző:Szuromi Lilla (kardiológus)
Cím:Long-Term Changes in the Biomarkers of Left Atrial Fibrosis after Pulmonary Vein Isolation for Paroxysmal and Persistent Atrial Fibrillation / Lilla Szuromi, Orsolya Hajas, Edina Nagy-Baló, Ildikó N. Forgács, László T. Nagy, Miklós Fagyas, Attila Tóth, Béla Nagy Jr., János Kappelmayer, Zoltán Csanádi
Dátum:2023
ISSN:1530-6550 2153-8174
Megjegyzések:Background: Atrial fibrillation (AF) is accompanied by inflammation and fibrosis to variable extent. The biomarkers of fibrosis were measured in patients with different forms of AF and cardiac status. Herein, we assessed the associations of the baseline concentrations of different biomarkers with the long-term success of pulmonary vein isolation (PVI) in patients with a structurally normal heart. Fur-thermore, we compared biomarker levels before and 3 years after ablation to gain further insights into the AF mechanism. Methods: Patients, undergoing PVI for paroxysmal/persistent AF were enrolled prospectively. Blood samples were obtained 24 hours before and 3 years after ablation. Serum cancer antigen 125 (CA-125), plasma Caspase-3, Galectin-3 and Cathepsin L concentrations were measured. Follow-up visits every 6 months included 12-lead electrocardiogram, 24-hour Holter, trans-telephonic monitoring as well as transtho-racic echocardiography after ablation. Biomarker levels, left ventricular ejection fraction and left atrial (LA) diameters at baseline and at the 3-year follow-up were compared in patients with versus without AF recurrence. Results: A total of 63 patients were enrolled (23 women; age 61.4 (& PLUSMN; 8.8) years). The acute isolation of all pulmonary veins was achieved in all patients. During a mean follow-up of 36.3 & PLUSMN; 6.3 months, AF recurrence was demonstrated in 26 (41.3%) patients. No significant differences were demonstrated in the levels of CA-125, Galectin-3, Caspase-3 and Cathepsin L pre-and post-ablation in patients with versus without AF recurrence. A significant decrease was detected in the concentrations of Caspase-3, Galectin-3 and Cathepsin L during follow-up with no difference in patients with versus without AF recurrence. A positive correlation was found between Caspase-3 levels and LA diameters in the AF recurrence group both before (r = 0.477; p = 0.018) and after the procedure (r = 0.533; p = 0.019). Conclusions: Our results demonstrated that the levels of CA-125, Caspase-3, Cathepsin L and Galectin-3 are not associated with AF recurrence after PVI in patients with a structurally normal heart and mainly paroxysmal AF. Except for CA-125, all the other biomarkers demonstrated a significant decrease during a 3 -year follow-up post-ablation. Furthermore, Caspase-3 levels demonstrated a positive correlation with LA dimensions in patients with AF recurrence.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Reviews in Cardiovascular Medicine. - 24 : 6 (2023), p. 171. -
További szerzők:Hajas Orsolya (1987-) Nagy-Baló Edina (1985-) (kardiológus) Forgács Ildikó Noémi (1992-) (biológus) Nagy László, T. (1974-) (informatikus) Fagyas Miklós (1984-) (orvos) Tóth Attila (1971-) (biológus) Nagy Béla Jr. (1980-) (labordiagnosztikai szakorvos) Kappelmayer János (1960-) (laboratóriumi szakorvos) Csanádi Zoltán (1960-) (kardiológus)
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM114386
035-os BibID:(WoS)001060165600001 (Scopus)85169334322
Első szerző:Tóth Emese (biotechnológus)
Cím:Distinct subsets of anti-pulmonary autoantibodies correlate with disease severity and survival in severe COVID-19 patients / Emese Tóth, Miklós Fagyas, Béla Nagy Jr., Ivetta Mányiné Siket, Blanka Szőke, Lilla Mártha, Mohamed Mahdi, Gábor Erdősi, Zsófia Pólik, János Kappelmayer, Zoltán Papp, Attila Borbély, Tamás Szabó, József Balla, György Balla, Attila Bácsi, Zoltán Szekanecz, Péter Bai, Attila Tóth
Dátum:2024
ISSN:2509-2715 2509-2723
Megjegyzések:Autoantibodies targeting the lung tissue were identified in severe COVID-19 patients in this retrospective study. Fifty-three percent of 104 patients developed anti-pulmonary antibodies, the majority of which were IgM class, suggesting that they developed upon infection with SARS-CoV-2. Anti-pulmonary antibodies correlated with worse pulmonary function and a higher risk of multiorgan failure that was further aggravated if 3 or more autoantibody clones were simultaneously present (multi-producers). Multi-producer patients were older than the patients with less or no autoantibodies. One of the identified autoantibodies (targeting a pulmonary protein of ~ 50 kDa) associated with worse clinical outcomes, including mortality. In summary, severe COVID-19 is associated with the development of lung-specific autoantibodies, which may worsen the clinical outcome. Tissue proteome-wide tests, such as the ones applied here, can be used to detect autoimmunity in the post-COVID state to identify the cause of symptoms and to reveal a new target for treatment.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Autoantibody
Clinical outcome
IgG
IgM
Lung
Mortality
Multi-producer
Post-COVID
SARS-CoV-2
Severe COVID-19
Megjelenés:GeroScience. - 46 : 2 (2024), p. 1561-1574. -
További szerzők:Fagyas Miklós (1984-) (orvos) Nagy Béla Jr. (1980-) (labordiagnosztikai szakorvos) Mányiné Siket Ivetta (1962-) (laborasszisztens) Szőke Blanka Mártha Lilla Mahdi, Mohamed (1979-) (orvos, tudományos segédmunkatárs) Erdősi Gábor Pólik Zsófia Kappelmayer János (1960-) (laboratóriumi szakorvos) Papp Zoltán (1965-) (kardiológus, élettanász) Borbély Attila (1978-) (kardiológus) Szabó Tamás Balla József (1959-) (belgyógyász, nephrológus) Balla György (1953-) (csecsemő és gyermekgyógyász, neonatológus) Bácsi Attila (1967-) (immunológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Bai Péter (1976-) (biokémikus) Tóth Attila (1971-) (biológus)
Pályázati támogatás:ÚNKP-23-5-DE-482
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.